Skip to main content
An official website of the United States government

Abbreviated MRI versus Standard Ultrasound for Hepatocellular Carcinoma Screening and Surveillance in Patients with Cirrhosis

Trial Status: active

This phase IV trial studies how well a new type of magnetic resonance imaging (MRI) exam called gadolinium contrast-enhanced abbreviated MRI (AMRI) works compared to a standard ultrasound exam to detect hepatocellular carcinoma (HCC) in patients with cirrhosis. Ultrasound is routinely used to monitor the livers of patients with cirrhosis who are at risk for HCC and to make decisions about their treatment. However, ultrasound has some limitations and is not the best choice for every patient. For these patients, computed tomography (CT) or MRI may be used. Gadolinium contrast is a liquid that is injected into the veins to make the organs more visible on MRI scans. This study will look at patients with cirrhosis to compare how well AMRI works compared to ultrasound to detect HCC.